Clinical trials: Helminth Infections
Helminthiasis
Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
The purpose of the study is to compare the pharmacokinetic profiles of two Albendazole tablet formulations manufactured under the different granulation processes in healthy Chinese adult males.
- Trial name
- NCT01755637
- Testing
- Albendazole
- Where
- 2 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Helminth Infections
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of mebendazole compared with placebo in pediatric participants with Helminth infections.
- Trial name
- NCT02034162
- Testing
- Mebendazole
- Where
- 3 sites in Ethiopia, Rwanda
- Volunteers
- 295 people
- Sponsor
- Janssen Research & Development, LLC
Schistosomiasis
L-PZQ ODT in Schistosoma Infected Children
The study would evaluate the safety and efficacy of L-praziquantel orodispersible (L-PZQ ODT) tablets in Schistosoma infected children aged 3 months to 6 years.
- Trial name
- NCT03845140
- Testing
- L-PZQ ODT 50 mg/kg, Biltricide®, L-PZQ ODT 60 mg/kg
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 288 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Onchocerciasis
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Onchocerciasis is a major public health problem in affected countries that causes disease-induced disability, and overall loss of economic productivity.
- Trial name
- NCT04913610
- Testing
- ABBV-4083, Albendazole
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 153 people
- Sponsor
- AbbVie
Schistosomiasis
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni.
- Trial name
- NCT02806232
- Testing
- Biltricide (racemate praziquantel) oral tablets, Racemate Praziquantel ODT, Levo Praziquantel ODT
- Where
- Germany
- Volunteers
- 444 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Fascioliasis
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6…
- Trial name
- NCT04230148
- Testing
- Egaten (Triclabendazole) 250 mg tablets
- Where
- 10 sites in Colombia, Egypt and 3 more
- Volunteers
- 301 people
- Sponsor
- Novartis Pharmaceuticals